Eshak I. Bahbah

Dr. Eshak I. Bahbah

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2019 in Environmental Science and Pollution Research
Verified
Journal Article
Closed access
PDF file
AEAbdelazim E. Elhelaly
Abdelazim E. Elhelaly
GAGadah AlBasher
Gadah AlBasher
SASaleh Alfarraj
Saleh Alfarraj
RARafa Almeer
Rafa Almeer
EBEshak I. Bahbah
Eshak I. Bahbah
Mohamed Abdel-DaimMohamed Abdel-Daim
Mohamed Abdel-Daim

3 April 2021 in Marine Drugs
Verified
Journal Article
Open access
PDF file
EBEshak I. Bahbah
Eshak I. Bahbah
SGSherief Ghozy
Sherief Ghozy
MAMohamed Attia
Mohamed Attia
Ahmed NegidaAhmed Negida
Ahmed Negida
TETalha Bin Emran
Talha Bin Emran
Jesus Simal-GandaraJesus Simal-Gandara
Jesus Simal-Gandara
Neurological disorders are diseases of the central and peripheral nervous system that affect millions of people, and the numbers are rising gradually. In the pathogenesis of neurodegenerative diseases, the roles of many signaling pathways were elucidated; however, the exact pathophysiology of neurological disorders and possible effective therapeutics have not yet been precisely identified. This necessitates developing multi-target treatments, which would simultaneously modulate neuroinflammation, apoptosis, and oxidative stress. The present review aims to explore the potential therapeutic use of astaxanthin (ASX) in neurological and neuroinflammatory diseases. ASX, a member of the xanthophyll group, was found to be a promising therapeutic anti-inflammatory agent for many neurological disorders, including cerebral ischemia, Parkinson’s disease, Alzheimer’s disease, autism, and neuropathic pain. An effective drug delivery system of ASX should be developed and further tested by appropriate clinical trials.

21 January 2020 in Environmental Science and Pollution Research
Verified
Journal Article
Closed access
PDF file
Mohamed Abdel-DaimMohamed Abdel-Daim
Mohamed Abdel-Daim
AAAbdelrahman Ibrahim Abushouk
Abdelrahman Ibrahim Abushouk
EBEshak I. Bahbah
Eshak I. Bahbah
Simona BungăuSimona Bungău
Simona Bungău
MAMohamed S. Alyousif
Mohamed S. Alyousif
SASaad Alkahtani
Saad Alkahtani

Verified
Journal Article
Open access
PDF file
ABAmira Yasmine Benmelouka
Amira Yasmine Benmelouka
MMMalak Munir
Malak Munir
ASAhmed Sayed
Ahmed Sayed
MAMohamed Attia
Mohamed Attia
MAMohamad M. Ali
Mohamad M. Ali
EBEshak I. Bahbah
Eshak I. Bahbah
Gliomas, which account for nearly a quarter of all primary CNS tumors, present significant contemporary therapeutic challenges, particularly the highest-grade variant (glioblastoma multiforme), which has an especially poor prognosis. These difficulties are due to the tumor’s aggressiveness and the adverse effects of radio/chemotherapy on the brain. Stem cell therapy is an exciting area of research being explored for several medical issues. Neural stem cells, normally present in the subventricular zone and the hippocampus, preferentially migrate to tumor masses. Thus, they have two main advantages: They can minimize the side effects associated with systemic radio/chemotherapy while simultaneously maximizing drug delivery to the tumor site. Another feature of stem cell therapy is the variety of treatment approaches it allows. Stem cells can be genetically engineered into expressing a wide variety of immunomodulatory substances that can inhibit tumor growth. They can also be used as delivery vehicles for oncolytic viral vectors, which can then be used to combat the tumorous mass. An alternative approach would be to combine stem cells with prodrugs, which can subsequently convert them into the active form upon migration to the tumor mass. As with any therapeutic modality still in its infancy, much of the research regarding their use is primarily based upon knowledge gained from animal studies, and a number of ongoing clinical trials are currently investigating their effectiveness in humans. The aim of this review is to highlight the current state of stem cell therapy in the treatment of gliomas, exploring the different mechanistic approaches, clinical applicability, and the existing limitations.

1 November 2017 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
Abdelrahman AbushoukAbdelrahman Abushouk
Abdelrahman Abushouk
MEMostafa Wanees Ahmed El-Husseny
Mostafa Wanees Ahmed El-Husseny
EBEshak I. Bahbah
Eshak I. Bahbah
AEAhmed Elmaraezy
Ahmed Elmaraezy
AAAya Ashraf Ali
Aya Ashraf Ali
Mohamed Abdel-DaimMohamed Abdel-Daim
Mohamed Abdel-Daim

1 July 2020 in Medical Hypotheses
Verified
Journal Article
Open access
EBEshak I. Bahbah
Eshak I. Bahbah
Ahmed NegidaAhmed Negida
Ahmed Negida
MAMohamed Attia
Mohamed Attia